One of the most robust forms of intellectual
property protection, a composition of matter patent grants
ChromaDex exclusive rights to the disodium salt form of NMNH
ChromaDex Corp. (NASDAQ:CDXC), the global authority on
nicotinamide adenine dinucleotide (NAD+) research with a focus on
healthy aging, today announced the broadening of its NAD+ precursor
intellectual property portfolio with the newly granted U.S. Patent
number 10,000,520 C1 covering the composition of matter for the
disodium salt of NMNH (dihydronicotinamide mononucleotide).
Co-owned with Queen's University Belfast (QUB), this patent
solidifies ChromaDex’s leadership in the NAD+ precursor space.
ChromaDex continuously evaluates and investigates
next-generation NAD+ precursors at the forefront of the burgeoning
healthy aging category. The company owns and licenses a robust and
secure portfolio of over 80 patents relating to its flagship
patented nicotinamide riboside (NR) ingredient, Niagen®, and other
NAD+ precursors including nicotinamide riboside triacetate (NRT),
reduced nicotinamide riboside (NRH), nicotinic acid riboside (NAR),
and now the newly granted NMNH patent.
Rob Fried, CEO of ChromaDex and Founder of Tru Niagen said,
"ChromaDex continues to lead the NAD+ field commercially and
scientifically, with the broadest patent portfolio of NAD+
precursors. As this industry continues to expand, we are committed
to innovation and maintaining the highest production quality
standards."
Not to be confused with NMN, which was banned as a dietary
supplement by the U.S. FDA in 2022, NMNH is chemically distinct
from NMN and a compound that has recently entered the U.S. market
as an NAD+ precursor. While preclinical studies have demonstrated
that NMNH can boost NAD+ levels when injected, further research is
needed to determine if it is orally bioavailable and safe as a
dietary supplement. Furthermore, NMNH is a new dietary ingredient
(NDI) which has not been properly notified to FDA, rendering its
legal status as a dietary supplement questionable at present.
One of the most robust forms of intellectual property
protection, a composition of matter patent, grants ChromaDex
exclusive rights to the disodium salt form of NMNH. Any company
that develops a product using the disodium salt form of NMNH would
infringe on ChromaDex’s patent.
In addition to the disodium salt of NMNH, ChromaDex has also
obtained protection for numerous other NMNH derivatives, including
metallic salts such as lithium, potassium, and magnesium. Further,
the patent adds protection for salt forms of NMNH. This broadens
ChromaDex’s protection and opens new avenues for future product
development and commercialization.
Granted by a three-examiner panel, this patent demonstrates the
diligence of ChromaDex’s innovative research and development
efforts.
For additional information on ChromaDex, visit
www.chromadex.com.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to commercial possibilities
for NMNH, prospective enforcement of patent rights, and ongoing
research and development efforts. Statements that are not a
description of historical facts constitute forward-looking
statements and may often, but not always, be identified by the use
of such words as "expects," "anticipates," "intends," "estimates,"
"plans," "potential," "possible," "probable," "believes," "seeks,"
"may," "will," "should," "could" or the negative of such terms or
other similar expressions. Risks that contribute to the uncertain
nature of these forward-looking statements include the impact of
the COVID-19 pandemic on our business and the global economy; our
history of operating losses and need to obtain additional
financing; the growth and profitability of our product sales; our
ability to maintain sales, marketing and distribution capabilities;
changing consumer perceptions of our products; our reliance on a
single or limited number of third-party suppliers; and the risks
and uncertainties associated with our business and financial
condition. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2023, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
About ChromaDex:
ChromaDex Corp. (NASDAQ:CDXC) is the global authority on
nicotinamide adenine dinucleotide (NAD+), with a focus on the
science of healthy aging. The ChromaDex team, comprised of
world-renowned scientists, works with independent investigators
from esteemed universities and research institutions around the
globe to uncover the full potential of NAD+. A vital coenzyme found
in every cell of the human body, NAD+ declines with age and
exposure to other everyday stressors. NAD+ depletion is a
contributor to age-related changes in health and vitality.
Setting the benchmark as the gold standard in scientific rigor,
safety, quality, and transparency, ChromaDex is the innovator
behind its clinically proven flagship ingredient, Niagen (patented
nicotinamide riboside, or NR), the most efficient and
superior-quality NAD+ booster available.
Niagen is the active ingredient in ChromaDex’s consumer
products, sold as the brand Tru Niagen®, the number one
healthy-aging NAD+ supplement in the United States†. Clinically
proven to increase NAD+ levels, Tru Niagen is helping people around
the world transform the way they age (available at
www.truniagen.com).
ChromaDex’s robust patent portfolio protects NR and other NAD+
precursors. ChromaDex maintains a website at www.chromadex.com, to
which ChromaDex regularly publishes copies of its press releases,
news, and financial information.
†Based on the top-selling dietary supplement brands by revenue
per the largest U.S. e-commerce marketplace (as of
3/1/2023-2/29/2024).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240819160149/en/
ChromaDex Media Contact: Kendall Knysch, Senior Director
of Media Relations & Partnerships 310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact: Ben Shamsian Lytham
Partners 646-829-9701 shamsian@lythampartners.com
ChromaDex (NASDAQ:CDXC)
過去 株価チャート
から 12 2024 まで 1 2025
ChromaDex (NASDAQ:CDXC)
過去 株価チャート
から 1 2024 まで 1 2025
